Company
Accipiter Biosciences
Accipiter Biosciences designs and develops de novo protein therapies — unbound by natural limitations — to address the world’s most complex diseases.
Also known as Accipiter Biosciences, Inc.
- Business model
- B2B
- Legal name
- Accipiter Biosciences, Inc.
Claim, correct or request removal
Record updated 19 October 2026
About
Accipiter Biosciences designs and develops de novo protein therapies — unbound by natural limitations — to address the world’s most complex diseases. Partnered with Pfizer and Kite Pharma, a Gilead Company.
Funding snapshot
- Total raised
- $14.2MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Undisclosed, $10.5M2026-07-21
Funding rounds
- Round, 2026
- $10.5M2026-07-21, SEC form D sold
- Round, 2024
- $13.6M2024-05-17, SEC form D sold, 15 investors
- Round, 2023
- $650K2023-04-19, SEC form D sold, 6 investors
Loading relationship preview